Shareholder rights law firm Robbins
Arroyo LLP announces that a purchaser of Apyx Medical Corporation
(NASDAQ: APYX) filed a class action complaint for alleged violations of
the Securities Exchange Act of 1934 between August 1, 2018 and April 1,
2019. Apyx is a medical technology company that develops J-Plasma, a
plasma-based surgical product for cutting, coagulation and ablation of
soft tissue. It is marketed and sold as Renuvion Cosmetic Technology.
View this information on the law firm's Shareholder Rights Blog: https://www.robbinsarroyo.com/apyx-medical-corporation/
Apyx Accused of Misleading Investors
According to the complaint, in August 2018, Apyx announced that it had
completed enrollment in its clinical study evaluating Renuvion and
represented that the results would support its 510(k) submission to the
FDA. Throughout December 2018 and January 2019, Apyx highlighted the
submission of the 510(k) application as a milestone. The truth was
revealed in February 2019 when White Diamond Research released a report
alleging that Apyx’s clinical study on the use of J-Plasma for dermal
resurfacing may have missed its endpoints. On this news, Apyx’s shares
fell nearly 25% to close at $6.40 per share on February 21, 2019. On
April 1, 2019, Apyx revealed it had withdrawn its 510(k) application for
regulatory clearance of J-Plasma in dermal resurfacing procedures,
citing concerns raised by the FDA. It also revealed that the clinical
study had missed its primary efficacy endpoint. On this news, Apyx
shares plummeted over 35% to close at $4.46 per share on April 2, 2019,
and continue to fall.
Apyx Shareholders Have Legal Options
Concerned shareholders who would like more information about their
rights and potential remedies can contact attorney Leo Kandinov at (800)
350-6003, lkandinov@robbinsarroyo.com
or via the shareholder
information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional investors
in shareholder derivative and securities class action lawsuits, and has
helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190422005587/en/
Copyright Business Wire 2019